Description

Inspire Medical Systems’ $150 Million Reimbursement Hit: Can Inspire V Still Deliver?

Inspire Medical Systems reported first quarter fiscal 2026 results characterized by modest revenue growth alongside ongoing challenges related to coding, reimbursement, and a government-mandated prior authorization program (WISeR). Revenue increased 1.6% year-over-year to $204.6 million, driven primarily by increased market penetration, although this growth was partially offset by estimated adverse impacts totaling approximately $20 million in the quarter due to coding uncertainties and WISeR-related delays. The company highlighted its efforts to manage these external headwinds through disciplined cost control, prioritizing revenue-generating activities, and investments aimed at long-term growth, including enhancements to patient care pathways, marketing, digital product experience, and research and development. Adjusted operating margin improved, supported by gross profit expansion from higher sales of the newer Inspire V system. Adjusted diluted earnings per share were $0.10, and operating cash flow increased by $20 million year-over-year to $12.